Category: Research

Novartis plans to start in-human Huntington’s disease trial in 2021

The Swiss pharmaceutical company Novartis is currently developing a pill for Huntington’s disease. Two days ago, the US Food and Drug Administration, FDA, granted an Orphan Drug Designation for the drug.  The drug is called branaplam (LMI070) and is administered in the form of a pill that you take through your mouth.  At the moment,…
Read more

Two new participants have enrolled in gene therapy trial

In June, two people enrolled in the first gene therapy trial for Huntington’s disease. Now, two more participants have joined the study uniQure states in a new press release.  UniQure is currently developing a gene therapy for Huntington’s disease. The drug candidate is called AMT-130 and is a gene therapy. In other words, it seeks to…
Read more

How to Ensure Equal Access to Treatment

The HEATED Project’s main aim is to ensure equal access to Huntington’s disease drugs by identifying barriers and overcoming them. The task force is therefore calling for more people to get involved.  The HEATED Project is a task force under European Huntington’s Disease Network (EHDN). Their main objective is to ensure equal access to drugs…
Read more

EHDN Bridging Event: – It’s a really rich time for us to be involved in Huntington’s disease

At the moment, there is a lot of research being done in the Huntington’s disease field. As Sarah Tabrizi from University College London stated during the meeting: ­– It’s a really rich time for us to be involved in Huntington’s disease. Get an update on some of the trials and studies here! Find all the…
Read more

Targeting Unstable Genes

Due to instability in the gene, Huntington’s disease symptoms may begin earlier in life. By targeting proteins involved in DNA damage repair, we might be able to reduce the levels of instability and delay disease progression. Many repair proteins work to maintain the machinery that copies DNA.  One of these proteins – so-called Huntington’s disease…
Read more

EHDN Newsletter: A special pandemic issue

The European Huntington’s Disease Network (EHDN) Newsletter appears three times a year. This year’s second edition is dedicated to the impact of Covid-19: the problems it has created but also the adaptability and the positive trends. In the newsletter, you can learn more about telemedicine. Here, Alzbeta Mühlbäck, our own doctor, states: – Though we…
Read more

Update from Wave: Webcast and Ongoing Huntington’s Disease Trials

On Tuesday 25 August, Wave Life Sciences is organising a webcast where they are planning to share exciting updates on their platform. In a recent press release, the company also announced that the results of their huntingtin lowering trials are expected in the first quarter of 2021. 10 August 2020, Wave Life Sciences issued a…
Read more

Join EHDN Virtual Bridging Event!

September 11 from 14:00 – 18:00 CEST, the European Huntington’s Disease Network will host Virtual Bridging Event where you can learn more about Huntington’s disease research and trials. Sign up now! Every other year, the European Huntington’s Disease Network (EHDN) hosts one of the world’s largest conferences dedicated solely to Huntington’s disease (HD). Despite taking a different form…
Read more

Watch the EAN Virtual Congress! FREE

The 6th Congress of the European Academy of Neurology (EAN), and First Virtual Congress, was the biggest meeting in neurology this year with more than 40.000 online participants. You can now watch all of the sessions online for a limited time and free of charge! The Congress was planned for May in Paris. Due to COVID-19,…
Read more

Latest Huntington’s disease news!

The EHDN Newsletter is here! The 39th edition is dedicated to ethics in Huntington’s disease. Find it here. The European Huntington’s Disease (EHDN) newsletter aims to communicate the network’s activities and other developments of interest in the field of Huntington’s disease to the lay community, healthcare professionals and scientists. It appears three times a year (March 1, July…
Read more